肠道微生物代谢物在肠易激综合征中的研究进展

Gut microbiota-derived metabolites in irritable bowel syndrome

摘要:

肠易激综合征(irritable bowel syndrome, IBS)是常见的胃肠道功能障碍疾病，以腹痛、腹胀、排便习惯改变等为典型临床症状。尽管IBS病因复杂且发病机制并未完全阐明，但越来越多的文献报道其发病与微生物-肠-脑轴调控失常密切相关。本文以肠道微生物衍生的代谢物神经递质、短链脂肪酸和胆汁酸代谢物为切入点，对其在内脏敏感、腹痛、腹泻和精神心理障碍等IBS症状发展中的作用进行系统综述，为以代谢物转化细菌为靶点治疗IBS提供理论支撑。

Abstract:

Irritable bowel syndrome (IBS) is the most common functional bowel disorder with the typical clinical symptoms such as abdominal pain, abdominal distension, and changes in bowel habits. Although the pathogenesis of IBS is complex and has not been fully understood, it has been proven to be related to the abnormal regulation of microbiota-gut-brain axis. The effects of derivative metabolites mediated by the microbiota, such as neurotransmitter, short-chain fatty acids, and bile acids metabolites, on the development of IBS symptoms (visceral sensitivity, abdominal pain, diarrhea and mental disorders) were systematically summarized. This study is expected to provide a new insight for the treatment of IBS with metabolites transforming bacteria as targets.